Innovent Biologics and Daiichi Sankyo to Commercialize Vanflyta® in China

Innovent Biologics and Japan-based Daiichi Sankyo have entered into an exclusive agreement to commercialize Vanflyta® in China. This collaboration is intended to expedite the availability of the drug for patients diagnosed with FLT3-ITD positive acute myeloid leukemia (AML) within the Chinese market.

Vanflyta®, also known as quizartinib, is a treatment developed for a specific and aggressive type of cancer. Under the terms of the licensing agreement, Innovent Biologics will be responsible for the drug's development and commercialization in China. Financial terms of the deal have not been disclosed.

Daiichi Sankyo holds global responsibility for the development and marketing of Vanflyta® in other regions. This partnership with Innovent Biologics supports the company's strategy to introduce significant cancer therapies to the Chinese market, one of the largest and fastest-growing pharmaceutical markets globally.

Regulatory approval from Chinese authorities for Vanflyta® is pending. Should approval be granted, Innovent Biologics will be responsible for its marketing in China. The disease targeted by Vanflyta® is characterized by a poor prognosis without novel treatment options.